| abstract |
The present disclosure provides novel T-cell receptors (TCRs), particularly at least one complementarity-determining region (CDR) thereof; T-cell expressing the TCR; A clone expressing the TCR; A vector encoding the TCR; A soluble version of the TCR; A pharmaceutical composition or immunogen or bispecific antibody or vaccine comprising the TCR, the cell, the clone or the vector; The use of the TCR or the cell or the clone or the vector or the pharmaceutical composition or immunogen or bispecific antibody or vaccine to treat cancer; And the TCR, the cell comprising the TCR, the clone, the vector, the pharmaceutical composition, an immunogen, a bispecific antibody, or a vaccine. |